Introduction
============

Acute liver injury (ALI) is a disease caused by drug poisoning, viral infection, immune reactions or vascular disorders, resulting in acute abnormal liver function. The clinical manifestation is acute hepatic dysfunction. ALI can subsequently develop into acute liver failure, which is characterized by rapidly progressing hepatic encephalopathy and multiple organ failure, with a poor prognosis and high mortality rate ([@b1-mmr-20-04-3095]). To date, no effective treatment for ALI has been found. Berberine (BBR) is an isoquinoline alkaloid found in plants of the families Berberidaceae, Papaveraceae, Ranunculaceae, Rutaceae and Physalis ([Fig. 1](#f1-mmr-20-04-3095){ref-type="fig"}) ([@b2-mmr-20-04-3095]). Studies have shown that BBR has many pharmacological functions, as well as antibacterial, anti-inflammatory, anti-tumor, cardioprotective and hypoglycemic properties; it also regulates lipid metabolism and immunosuppression, and protects the central nervous system ([@b3-mmr-20-04-3095]--[@b6-mmr-20-04-3095]). A previous study by the authors found that 0.004 mg/ml BBR exerts a protective function against lipopolysaccharide-induced inflammatory injury to hepatocytes in rats, but doses \>0.005 mg/ml can increase reactive oxygen species (ROS) levels in L929 cells ([@b7-mmr-20-04-3095]). In the current study, to further explore the effects of BBR on liver damage, CCl~4~-induced ALI in rats was used as a pathological model, and BBR was used as an interventional therapy. Before and after the treatment, the macroscopic, biochemical and histological changes in the liver were observed. The mRNA expression levels of nuclear factor erythroid 2-related factor 2 (Nrf2)-kelch-like ECH-associated protein 1 (Keap1)-antioxidant responsive element (ARE) signaling pathway-related genes \[*Nrf2, Keap-1*, NAD(P)H quinone dehydrogenase 1 (*NQO-1*) and heme oxygenase 1 (*HO-1*)\], p53 signaling pathway-related genes (*p53, Bcl-2* and *Bcl-xL*), and HO-1 protein expression, were detected. The results obtained may provide an experimental basis for the clinical use of BBR in the treatment of liver injury.

Materials and methods
=====================

### Chemicals

BBR (Sigma-Aldrich; Merck KGaA), BBR standard (Dalian Meilun Biotech Co., Ltd.), silymarin (Shanghai Yuanye Biotechnology Co., Ltd.), CCl~4~ (Xilong Chemical Co., Ltd.), detection kits for ROS, total superoxide dismutase (T-SOD), catalase (CAT), malondialdehyde (MDA), glutathione (GSH), aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) (all from Nanjing Jiancheng Bioengineering Institute), RNA extract (Google Biotechnology Co., Ltd., Wuhan, China), alcohol, isopropanol and trichloromethane (all from Sinopharm Chemical Reagent Co., Ltd.) were purchased from the suppliers indicated. HyPure™ molecular biology grade water was purchased from HyClone; GE Healthcare Life Sciences. The RevertAid First Strand cDNA Synthesis kit was procured from Thermo Fisher Scientific, Inc. FastStart Universal SYBR Green Master (Rox) was supplied by Roche Diagnostics. Primers were synthesized by Sangon Biotech Co., Ltd.

### Animals

In total, 48 5-week-old male Sprague-Dawley (SD) rats (180--200 g) were obtained from Guangzhou TianCheng Medical Technology Co., Ltd. \[animal license no. SCXK (Su) 2014--0007\]. The animals were maintained in standard housing facilities (24±1°C; 45±5% relative humidity; 12-h light/dark cycle), and fed a standard laboratory diet, with *ad libitum* access to water. All animals were given a week to acclimatize before the experiment. All procedures were in strict accordance with the Chinese legislation on the use and care of laboratory animals and the guidelines established by the Institute for Experimental Animals of Anhui Agriculture University, and were approved by the Anhui Agriculture University Committee on Animal Care and Use.

### Animal grouping and treatment

The 48 SD rats were randomly divided into six groups (n=8): Control; model; positive control (PC); BBR low-dose (BL); BBR middle-dose (BM); and BBR high-dose (BH). The rats of the BC, BM and BH groups received BBR (5, 10 and 15 mg/kg body weight, respectively) orally for 7 consecutive days. The positive control (PC) group animals were given silymarin (150 mg/kg). The control and model animals were administered distilled water orally for 7 days. A total of 6 h after the last gavage, the model, PC, BL, BM and BH rats were given 50% CCl~4~ oil solution (1 ml/kg, intraperitoneally), and the control rats were given the same amount of soybean oil solvent. At 24 h after the injection, the rats were weighed and sacrificed. Blood samples from the heart (3--5 ml) and livers were collected and a liver autopsy was conducted, followed by several other laboratory tests, as described below.

### Pathological examination

The size, color, smoothness, hardness and elasticity of the liver were visually observed, and common pathological changes, such as swelling, nodules, necrosis, degeneration, hemorrhage and congestion, were noted.

### Biochemical indices of the liver (AST and ALT)

Non- anticoagulant samples were centrifuged at 4°C, 1,106 × g for 5 min to separate the serum. Serum levels of AST and ALT were detected using an automatic biochemistry analyzer (Catalyst Dx; IDEXX Laboratories, Inc.).

### Detection of the ROS level in hepatocytes

The fresh liver was cut into several 1 mm^3^ pieces using ophthalmic scissors, digested using trypsin, and filtered to obtain a single-cell suspension. The ROS level was detected by flow cytometry (FACSCalibur; Becton, Dickinson and Company), according to the instructions supplied with the ROS test kit. CellQuest version 6.0 (Becton, Dickinson and Company) was used for the collection and analysis of data.

### Detection of biochemical indices in liver tissue

A portion of the liver was taken and homogenized using a tissue homogenizer (KZ-II; Servicebio) to obtain a 10% tissue homogenate, which was centrifuged for 10 min at 1,106 × g at 4°C and the supernatant collected. Levels of T-SOD, MDA, and GSH were spectrophotometrically detected (Pharo 300; Merck KGaA).

### Detection of HO-1 protein expression in hepatic tissues by western blotting

Total proteins were extracted after cell lysis using RIPA buffer (Servicebio), for western blotting and immunoprecipitation with PMSF. Proteins were quantified using the bicinchoninic acid assay. Equal amounts of protein were loaded onto a 12% SDS-PAGE gel, electrophoresed, transferred to a nitrocellulose membrane, and blocked with 5% skim milk for 1 h at room temperature. The membrane was incubated with primary antibodies against anti-HO-1 (1:1,000; cat no. 10701-1-AP; Wuhan Sanying Biotechnology) and GAPDH (1:1,000; cat. no. GB12002; Servicebio) at 4°C overnight and then washed with TBS with Tween-20, followed by incubation with a peroxidase-labeled secondary antibody for 30 min at room temperature (1:3,000; cat. no. GB23303; Servicebio). Protein visualization was achieved using enhanced chemiluminescence western blotting reagents (Servicebio) and the multi-spectral imaging system (VersaDoc™ 4000 MP; Bio-Rad Laboratories, Inc.).

### Detection of the expression of Nrf2, Keap-1, NQO-1, HO-1, P53, Bcl-2 and Bcl-xL mRNA by reverse transcription-quantitative PCR(RT-qPCR)

Liver tissues were stored at −80°C. Liver samples were ground with liquid nitrogen, and the total liver RNA was extracted with TRIzol^®^ reagent (Thermo Fisher Scientific, Inc.) and then reverse-transcribed to cDNA, according to the manufacturer\'s instructions. Samples were then amplified using qPCR, as specified in the instructions supplied with the FastStart Universal SYBR Green Master (Rox) kit. PCR conditions were as follows: 95°C for 10 min, 40 cycles of 95°C for 15 sec and 60°C for 1 min, and 95°C for 15 sec. The relative mRNA expression of target genes compared to GAPDH was calculated using the 2^−ΔΔCq^ method ([@b8-mmr-20-04-3095]).

### Histopathological examinations

Rat liver tissues were fixed in a 4% buffered formalin solution for 7 days at room temperature and dehydrated using a standard alcohol-xylol process (75, 85, 95 and 100% alcohol, alcohol:xylene=1:1, xylene), embedded in paraffin, cut into 5-µm-thick sections using an LS-2055+ paraffin semiautomatic machine (Shenyang LongShou Electronic Instrument Co., Ltd), and stained with hematoxylin and eosin at room temperature as follows: xylene I, 10 min; xylene II, 10 min; 100% alcohol I, 2 min; 100% alcohol II, 2 min; 95% alcohol I, 2 min; 95% alcohol II, 2 min; 85% alcohol, 2 min; hematoxylin, 30 sec; color separation solution, 3 sec; anti-blue solution, 10 sec; eosin, 10 sec; 85% alcohol, 2 min; 95% alcohol II, 2 min; 95% alcohol I, 2 min; 100% alcohol II, 2 min; 100% alcohol I, 2 min; xylene II, 2 min; and xylene I, 2 min. Liver sections were examined by light microscopy using a biological microscope (magnification, ×400; CX21FS1; Olympus Corporation).

### Statistical analysis

Data were analyzed using IBM SPSS 19.0 (IBM Corp.), and the results expressed as the mean ± SEM. One-way analysis of variance was used to compare the groups, followed by Duncan\'s test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Liver pathological changes

The livers of the control group were reddish-brown, with a smooth surface, neat edge and uniform thickness. The livers of the model group were yellowish-brown and overtly swollen, with necrotic spots on the surface and a rounded edge. The histopathological lesions were effectively attenuated in the drug-treated groups, to varying extents, and the livers of the BM, BH and PC groups had the least swelling, while necrotic spots on the surface were markedly reduced.

### Levels of serum ALT, AST and ALP

Compared with the control group, serum ALT, AST, and ALP levels in the model group were increased (P\<0.05). Rats of the BBR-treated and PC groups exhibited a decrease (P\<0.05) in serum ALT, AST and ALP levels when compared with the model group; these differences were more evident in the BH group than in the BL, BM and PC groups ([Fig. 2](#f2-mmr-20-04-3095){ref-type="fig"}).

### Levels of GSH, T-SOD and MDA in hepatic tissues

Compared with the control group, GSH and T-SOD levels in hepatic tissues in the model group were decreased (P\<0.05) and the MDA content was increased (P\<0.05). Compared with the model group, liver GSH levels in the BM and BH groups were increased (P\<0.05), whereas there were no significant (P\>0.05) difference between the model and BL groups. T-SOD levels in the BBR-treated groups were comparable (P\>0.05) to those in the model rats, but the liver MDA level in the BH and PC groups was significantly (P\<0.05) decreased ([Fig. 3](#f3-mmr-20-04-3095){ref-type="fig"}).

### Level of ROS in hepatocytes

Compared with the control group, the liver ROS level of the model group was increased (P\<0.05). Rats of the BBR-treated and PC groups exhibited a significant (P\<0.05) decrease in the ROS level in hepatocytes when compared with the model group. The ROS level of the BH group was similar to that of the control group (P\>0.05; [Fig. 4](#f4-mmr-20-04-3095){ref-type="fig"}).

### Levels of Nrf2, Keap-1, NQO-1 and HO-1 mRNA in hepatic tissue

Compared with the control group, the liver *Nrf2* mRNA level of the model group was decreased (P\<0.05). Compared with the model group, BL, BM and PC rats showed upregulation of *Nrf2* mRNA expression (P\>0.05), but only BH rats exhibited a significant upregulation (P\<0.05) of *Nrf2* mRNA expression. Although the expression of *Keap-1* mRNA in rat hepatic tissues in the model group was increased, it was not significantly different (P\>0.05) from that in the control group. BBR upregulated (P\<0.05) the expression of *Keap-1* mRNA in comparison to the model group. The expression of *HO-1* mRNA in rat hepatic tissues in the model group was decreased, but the difference was not significant (P\>0.05) compared with the control group. A low dose of BBR slightly upregulated the expression of *HO-1* mRNA (P\>0.05), and middle or high doses of BBR significantly (P\<0.05) upregulated the expression of *HO-1* mRNA. Rats of the model group exhibited a decrease (P\<0.05) in the *NQO-1* mRNA level in hepatic tissues when compared with the control group. In comparison to the model group, BBR upregulated (P\<0.05) the expression of *NQO-1* mRNA in the rat hepatic tissue, and silymarin slightly upregulated (P\>0.05) the expression of *NQO-1* mRNA ([Fig. 5](#f5-mmr-20-04-3095){ref-type="fig"}).

### Levels of p53, Bcl-2, and Bcl-xL mRNA in hepatic tissues

The expression of *p53* mRNA was increased (P\<0.05) in the hepatic tissue of the model group compared with the control group. The expression of *p53* mRNA in the hepatic tissue in the BBR-treated groups and the silymarin group was decreased (P\<0.05) compared with the model group. The expression of *Bcl-2* mRNA was lower (P\<0.05) in the model group than the control group, whereas those in the low-dose BBR group and the silymarin group were higher (P\<0.05) than that in the model group while there was no significant (P\>0.05) difference between the medium- and high-dose BBR groups and the model group. In comparison to the control group, the expression of *Bcl-xL* mRNA was somewhat decreased (P\>0.05) in the liver tissue of the model group while those in the low-, medium-and high-dose BBR groups, and the silymarin group, were increased (P\<0.05; [Fig. 6](#f6-mmr-20-04-3095){ref-type="fig"}).

### Effects of BBR on liver histopathology

The control group livers presented with normal architecture of the hepatocytes and intact cytoplasm. The structure of the hepatic lobule was clear, and the hepatic cord was arranged radially. The nucleus of the hepatocyte was centrally located. The hepatocytes in the model group showed an irregular arrangement, as well as cellular edema and necrosis. The cytoplasmic vacuolization of hepatocytes was noticeable. Hepatocyte edema was reduced in the BBR-treated and PC groups, and necrotic hepatocytes and fatty degeneration of hepatocytes was significantly reduced ([Fig. 7](#f7-mmr-20-04-3095){ref-type="fig"}).

### Effects of BBR on HO-1 protein

The western blotting results showed a decrease in the expression of HO-1 in the model group compared with the control group, and that in the BBR-treated and PC groups was increased when compared with the model group ([Fig. 8](#f8-mmr-20-04-3095){ref-type="fig"}).

Discussion
==========

The liver is the main organ involved in the metabolism of drugs and toxic chemicals of the human body and is highly susceptible to damage caused by drugs, poisons and viruses. The ALI model generated by CCl~4~ treatment is widely used in the study of chemical liver injury and hepatoprotective screening ([@b9-mmr-20-04-3095],[@b10-mmr-20-04-3095]). The mechanism of ALI induced by CCl~4~ is complex. Oxidative stress, lipid peroxidation, changes in the activity and content of metabolic enzymes, cytokines, apoptosis, and many other factors are involved in this process ([@b11-mmr-20-04-3095]--[@b13-mmr-20-04-3095]); oxidative stress is considered to be the main pathogenetic process of liver injury induced by CCl~4~. Oxidative stress means that when stimulated by certain harmful factors, the body will produce excessive high-activity molecules, such as ROS and reactive nitrogen species, resulting in an imbalance between the oxidation and antioxidant defense systems. Neutrophil inflammatory infiltration occurs, and a large number of oxidative intermediates are produced, causing tissue cell damage ([@b14-mmr-20-04-3095]). When hepatocytes are damaged, cell membrane permeability will increase and cytoplasmic transaminases, such as ALT and AST, can be released into the blood in large amounts ([@b15-mmr-20-04-3095],[@b16-mmr-20-04-3095]). MDA, the product of membrane lipid peroxidation, can exacerbate cell membrane damage. When CCl~4~ induces lipid peroxidation damage in the liver, HO-1, GSH peroxidase, SOD and GSH are reduced to varying degrees ([@b17-mmr-20-04-3095]).

Serum aminotransferases ALT, AST and ALP are the most effective indicators of early liver injury ([@b18-mmr-20-04-3095]). When hepatocytes are damaged, ALT and AST are released in large amounts into the blood, and serum ALT and AST levels are increased. In this experiment, the levels of serum ALT, AST and ALP in the model group were significantly increased. After treatment with BBR, the levels of serum ALT, AST and ALP were significantly decreased, indicating that BBR can alleviate CCl~4~-induced ALI to a certain extent, consistent with the histopathological results.

SOD and GSH are important antioxidant enzymes in the body, which can effectively eliminate free radicals and inhibit free radical-induced lipid peroxidation ([@b19-mmr-20-04-3095]). As the final metabolite of lipid peroxidation, the MDA level reflects the degree of oxidative stress caused by toxophores ([@b20-mmr-20-04-3095]). Liu *et al* ([@b10-mmr-20-04-3095]) showed that CCl~4~ could disrupt the antioxidant system, reduce the levels of GSH and SOD, and raise the level of MDA, promoting further development of liver damage. The results of the current study showed that BBR could ameliorate CCl~4~-induced liver injury by increasing T-SOD and GSH levels and reducing MDA, indicating that the hepatoprotective effects of BBR may be related to antioxidative stress.

The Nrf2-ARE signaling pathway is a key pathway for cellular antioxidant stress, and the antioxidant enzyme system and phase II detoxification enzymes regulated by this signaling pathway can eliminate harmful substances, such as ROS ([@b21-mmr-20-04-3095],[@b22-mmr-20-04-3095]). The activated Nrf2-ARE signaling pathway can induce the transcription of protective genes, such as *HO-1*, glutathione-S-transferase and *NQO1*, to resist oxidative stress damage caused by various stimulating factors ([@b23-mmr-20-04-3095]). Hsu *et al* ([@b24-mmr-20-04-3095]) demonstrated that BBR could promote the nuclear translocation of Nrf2 in motor neuron-like cell lines. According to Chen *et al* ([@b25-mmr-20-04-3095]), BBR can upregulate the transcription of the *HO-1* gene in primary astrocytes. Additionally, Zhang *et al* ([@b26-mmr-20-04-3095]) reported that BBR further activates Nrf2 by activating the AMPK pathway, PI3K/Akt pathway and the p38 pathway, increasing the expression of *HO-1* and *SOD*, reducing ROS production, and, in turn, attenuating oxidative stress. The results presented herein showed that BBR could significantly reduce the level of ROS in the body and upregulate the expression of *Nrf2, Keap-1, NQO-1* and *HO-1* in cells, further indicating that the hepatoprotective effect of BBR is related to antioxidative stress.

When DNA damage occurs, or the cells are stimulated by ROS, the tumor suppressor p53 may be involved in the regulation of apoptosis. p53 promotes apoptosis by upregulating the pro-apoptotic gene *Bax* and downregulating the expression of anti-apoptotic genes *Bcl-2* and *Bcl-xL* ([@b27-mmr-20-04-3095],[@b28-mmr-20-04-3095]). Tiwari *et al* ([@b29-mmr-20-04-3095]) revealed that *HO-1* produced by oxidative stress could inhibit apoptosis by upregulating the expression of Bcl-2 and Bcl-xL proteins. Sha *et al* ([@b30-mmr-20-04-3095]) indicated that BBR hydrochloride could induce apoptosis in human gastric cancer cells, and its mechanism may be closely related to the upregulation of Bax and p53 protein, and downregulation of Bcl-2 protein.

The results of the present study showed that BBR could significantly reduce the expression of *p53* mRNA, and increase the expression of *Bcl-2* and *Bcl-xL* mRNA, to different extents. BBR effectively protects against CCl~4~-induced ALI in rats, and its mechanism may inhibit ROS production, reduce serum ALT, AST and ALP levels, and increase T-SOD, GSH and MDA. BBR activates the Nrf2-Keap1-ARE signaling pathway, to regulate the expression of *Nrf2, Keap-1, NQO-1* and *HO-1* genes, and inhibits hepatocyte apoptosis by downregulating the *p53* gene and upregulating the *Bcl-xL* and *Bcl-2* genes.

One limitation of the present study was the lack of TUNEL staining to detect the level of apoptosis before and after treatment with BBR. Future studies will use TUNEL staining to assess apoptosis. Further *in vitro* experiments are required to elucidate the upstream and downstream pathways of Nrf2-Keap1-ARE.
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Levels of ROS in hepatocytes from the different groups. (A) Levels of ROS in hepatocytes from the different groups. (B) Levels of ROS in hepatocytes of the control group. (C) Levels of ROS in hepatocytes of the model group. (D) Levels of ROS in hepatocytes of the BL group. (E) Levels of ROS in hepatocytes of the BM. (F) Levels of ROS in hepatocytes of the BH group. (G) Levels of ROS in hepatocytes of the PC group. n=8 per group. \*P\<0.05 vs. control; ^\#^P\<0.05 vs. model. BL, berberine low-dose; BM, berberine middle-dose; BH, berberine high-dose; PC, positive control; ROS, reactive oxygen species; DCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetate.
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![Liver pathological changes in rats. (A) Liver pathology of the control group. (B) Liver pathology of the model group. (C) Liver pathology of the BBR low-dose group. (D) Liver pathology of the BBR middle-dose group. (E) Liver pathology of the BBR high-dose group. (F) Liver pathology of the positive control group. n=8 per group. Magnification, ×400. BBR, berberine.](MMR-20-04-3095-g07){#f7-mmr-20-04-3095}
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